The Great Lakes Zephyr - Wind Energy & Hydrogen Journal

UW-Madison News Release--Speeding Vaccine Production

FOR IMMEDIATE RELEASE
10/31/05

NOTE TO REPORTERS: Kawaoka is traveling, but should be reachable by email.

PHOTO EDITORS: High-resolution images are available for downloading at
http://www.news.wisc.edu/newsphotos/fluVirus.html

CONTACT: Yoshihiro Kawaoka, (608) 265-4925, kawaokay@vetmed.wisc.edu

UW-MADISON SCIENTISTS REPORT A NEW METHOD TO SPEED BIRD FLU VACCINE PRODUCTION

MADISON - In the event of an influenza pandemic, the world's vaccine manufacturers will be in a race against time to forestall calamity.

But now, thanks to a new technique to more efficiently produce the disarmed viruses that are the seed stock for making flu vaccine in large quantities, life-saving inoculations may be available more readily than before. The work is especially important as governments worldwide prepare for a predicted pandemic of avian influenza.

Writing today (Oct. 31, 2005) in the online edition of the Proceedings of the National Academies of Science (PNAS), a team of researchers from the University of Wisconsin-Madison and the University of Tokyo report a new way to generate genetically altered influenza virus. The lab-made virus - whose genes are manipulated to disarm its virulent nature  - can be seeded into chicken eggs to generate the vaccine used in inoculations, which prepare the human immune system to recognize and defeat the wild viruses that spread among humans in an epidemic or pandemic.

In their report, a team led by UW-Madison virologists Yoshihiro Kawaoka and Gabriele Neumann, describes an improved "reverse genetics" technique that makes it easier to make a seed virus in monkey kidney cells, which, like tiny factories, churn out millions of copies of the disarmed virus to be used to make vaccines.

In nature, viruses commandeer a cell's reproductive machinery to make new virus particles, which go on to infect other cells and make yet more virus particles.  Vaccine makers use a monkey kidney cell line to make non-virulent viruses that serve as the raw material for vaccines.

The technique reported by the Wisconsin team improves upon a previous reverse genetics method (developed by Kawaoka's group in 1999) by significantly reducing the number of plasmid vectors required to ferry viral genes into the monkey kidney cells used to produce the virus particles to make vaccines.

"Compared to other types of cells, which are not approved for vaccine production, it is not always easy to introduce plasmids into the monkey kidney cells, which are approved for such use," says Kawaoka, an influenza expert and a professor of pathobiological sciences in UW-Madison's School of Veterinary Medicine.  Monkey kidney cells are used routinely for generation of seed strains for vaccine production because they are not known to carry any unknown infectious agents and do not cause tumors.

According to Kawaoka, "application of the new system may be especially advantageous in situations of outbreaks of highly pathogenic avian influenza viruses."

When a new strain of highly virulent influenza emerges to infect humans, vaccine makers must tailor their vaccines to match it because, genetically, the virus is always different. The process is a race against time and can take months depending on how quickly new strains are identified, genetically disarmed and subsequently generated in the lab for use to make vaccines in large quantities.

The new technique promises to ensure ready generation of seed strains for the production of vaccines required to blunt the spread of influenza. In the event of an outbreak of especially virulent strains of influenza, such as the H5N1 or "bird flu" viruses now being monitored by scientists, any efficiency in the manufacture of vaccines will be important.

The method devised by Kawaoka and his colleagues reduces the number of plasmids required to introduce viral genes into the monkey kidney cell lines used to mass produce the deactivated virus for use in vaccine manufacture. "By reducing the number of plasmids, we increase the efficiency of virus production," Kawaoka explains.

In addition to Kawaoka, the new PNAS report was authored by Neumann of the UW-Madison School of Veterinary Medicine, Ken Fujii of the University of Tokyo's Institute of Medical Sciences, and Yoichiro Kino of Japan's Chemo-Sero Therapeutic Research Institute. The work was funded by grants from the U.S. National Institutes of Health, the Ministries of Education, Culture, Sports, Science and Technology of Japan, and by the Core Research for Evolutional Science and Technology.

# # #

- Terry Devitt, (608) 262-8282, trdevitt@wisc.edu



****************************************************
For questions or comments about UW-Madison's email
news release system, please send an email to:
releases@news.wisc.edu

For more UW-Madison news, please visit:
http://www.news.wisc.edu/

University Communications
University of Wisconsin-Madison
27 Bascom Hall
500 Lincoln Drive
Madison, WI 53706

Phone: (608) 262-3571
Fax: (608) 262-2331